EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Extracellular Vesicle‐Based Antitumor Nanomedicines

Mingfeng Li, Yanfei Liu, Fei Liu, Qiwen Chen, Lishang Xu, Zhongyu Cheng, Yifu Tan, Zhenbao Liu iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202403903 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Mingfeng Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, P. R. China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Nanomedicine, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 248 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation for Distinguished Young Scholars, Innovation-Driven Project of Central South University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular vesicles (EVs) have emerged as promising bioactive carriers for delivering therapeutic agents, including nucleic acids, proteins, and small‐molecule drugs, owing to their excellent physicochemical stability and biocompatibility. However, comprehensive reviews on the various types of EV‐based nanomedicines for cancer therapy remain scarce. This review explores the potential of EVs as antitumor nanomedicines. Methods for EV extraction, drug loading, and engineering modifications are systematically examined, and the strengths and limitations of these technical approaches are critically assessed. Additionally, key strategies for developing EV‐based antitumor therapies are highlighted. Finally, the opportunities and challenges associated with advancing EVs toward clinical translation are discussed. With the integration of multiple disciplines, robust EV‐based therapeutic platforms are expected to be manufactured to provide more personalized and effective solutions for oncology patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesNanomedicineAntineoplastic AgentsNeoplasmsHumansAnimalsDrug Delivery SystemsDrug Carriers

Stichwörter der Autor:innen

antitumor immunityextracellular vesiclestargeted delivery systemstumor microenvironmenttumor vaccines

Substanzen

Antineoplastic AgentsDrug Carriers

Autor:innen und Institutionen

  • Department of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, P. R. China.
  • Department of Pharmaceutical Engineering, College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, 410083, P. R. China.
  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Molecular Imaging Research Center of Central South University, Changsha, Hunan, 410008, P. R. China.

ORCID-Profile: Zhenbao Liu

Förderung

  • National Natural Science Foundation of China
  • Hunan Provincial Natural Science Foundation for Distinguished Young Scholars
  • Innovation-Driven Project of Central South University
  • Hunan Provincial High-Level Health Talents
  • Joint Fund of the Hunan Provincial Natural Science Foundation and the Hunan Medical Products Administration

Zitieren

APA

Li, M., Liu, Y., Liu, F., Chen, Q., Xu, L., Cheng, Z., Tan, Y., & Liu, Z. (2025). Extracellular Vesicle‐Based Antitumor Nanomedicines. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403903

Vancouver

Li M, Liu Y, Liu F, Chen Q, Xu L, Cheng Z, et al. Extracellular Vesicle‐Based Antitumor Nanomedicines. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403903

BibTeX
@article{Li2025,
  author = {Li, Mingfeng and Liu, Yanfei and Liu, Fei and Chen, Qiwen and Xu, Lishang and Cheng, Zhongyu and Tan, Yifu and Liu, Zhenbao},
  title = {Extracellular Vesicle‐Based Antitumor Nanomedicines},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202403903}
}
Kostenlos starten →